NovoCure Appoints Christoph Brackmann as CFO to Support Growth and Expansion Plans

NovoCure Strengthens Financial Leadership Amid Expansion Plans

NovoCure, a global leader in oncology based in Switzerland, announces the appointment of Christoph Brackmann as its new Chief Financial Officer (CFO), effective January 1, 2025. As the company prepares to broaden its product portfolio and extend its global presence, Brackmann's leadership is expected to play a pivotal role. He begins his tenure as a Senior Financial Advisor, bringing a wealth of experience from his previous role as Senior Vice President of Finance at Moderna, Inc. During his time at Moderna, Brackmann was instrumental in building the finance team and navigating the company’s swift growth during the COVID-19 pandemic, demonstrating his capability in managing financial operations during high-pressure situations.

Current CFO Ashley Cordova, who will transition to the CEO position, expresses strong confidence in Brackmann's strategic insight and industry knowledge. Cordova acknowledges that the company is entering a critical phase of expansion, and Brackmann’s extensive background in finance will be invaluable as NovoCure seeks to innovate and enhance its offerings in cancer treatment. With a career spanning over two decades in finance at notable organizations like Shire plc, Eli Lilly, and Novartis, Brackmann has established a reputation for effective financial management and strategic planning. His academic foundation, which includes an MBA from the SDA Bocconi School of Management and a bachelor's degree from the University of Mannheim, further supports his qualifications for this key role.

NovoCure is renowned for its pioneering Tumor Treating Fields therapy, which offers hope to adult patients battling aggressive cancers such as glioblastoma and non-small cell lung cancer. The company is actively engaged in clinical trials to explore additional applications of its innovative therapy, underscoring its commitment to enhancing patient survival rates. As NovoCure positions itself for future growth, the integration of Brackmann into its leadership is seen as a strategic move to ensure robust financial oversight and support the company’s ambitious goals in the oncology sector.

In addition to Brackmann's appointment, NovoCure’s operational strategy reflects its international ambition, with a global headquarters in Switzerland and a U.S. headquarters in Portsmouth, New Hampshire. This dual presence allows the company to leverage diverse markets and better serve its mission of transforming cancer treatment. As the organization evolves, the expertise of its leadership team, particularly in financial stewardship, will be crucial in executing its vision for the future.